

VIA ELECTRONIC MAIL

Office of the Vermont Attorney General 109 State Street Montpelier, Vermont 05609 ago.highcostprescriptiondrugs@vermont.gov

March 12, 2024

Dear Sir/Madam,

In compliance with 18 V.S.A. § 4637, Hikma Pharmaceuticals USA Inc. ("Hikma") hereby provides the Office of Attorney General with notice that Hikma has introduced new generic prescription drugs (the "Products") at a wholesale acquisition cost that is over the threshold set for a specialty drug under the Medicare Part D program. A schedule identifying such Products is set forth as Exhibit A.

Additionally, in compliance with 18 V.S.A. § 4637(c) as further refined by 18 V.S.A. § 4637 (d), Hikma hereby provides the following information which is in the public domain or publicly available:

- (1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;
 - a. These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only.
- (2) The estimated volume of patients who may be prescribed the drug;
 - a. The estimated average number of patients per month is unknown to Hikma.
- (3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;
 - a. Not applicable.
- (4) The date and price of acquisition if the drug was not developed by the manufacturer;
 - a. Hikma did not acquire this product.

Finally, Hikma would like to confirm that: (i) the Office of the Attorney General has not yet provided a format for submissions under this section; and (ii) this notice is an appropriate means of submitting the required information.

Very truly yours,

Heather Skye Patrick Sr. Analyst, Legal Affairs

Heather S. Patrick

www.hikma.com



EXHIBIT A

NDC	PRODUCT	DATE OF INTRO TO MARKET	WAC
00054-0652-25	Vigabatrin Tablets USP, 500mg, 1 bottle of 100	3/11/2024	\$6,212.31